CASI Pharmaceuticals (CASIF) Total Debt (2021 - 2025)
CASI Pharmaceuticals' (CASIF) quarterly Total Debt came in at $19.2 million in Q4 2025, up 4.38% YoY from $18.4 million in Q4 2024, and up 4.38% on a QoQ basis from $18.4 million in Q4 2024.
CASI Pharmaceuticals (CASIF) Total Debt (2021 - 2025) Analysis & Trends
CASI Pharmaceuticals (CASIF) has 5 years of Total Debt data on file, last reported at $19.2 million in Q4 2025.
- Quarterly Total Debt rose 4.38% year-over-year to $19.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $19.2 million (up 4.38% YoY) and the FY2025 annual result came in at $19.2 million, up 4.38% from the prior year.
- Total Debt climbed to $19.2 million in Q4 2025, from $18.4 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $18.9 billion in Q4 2023 to a low of $11.8 million in Q4 2022.
- A 5-year average of $5.3 billion and a median of $18.6 million in 2024 frame the typical range for Total Debt.
- Annual changes were most pronounced in 2023 — Total Debt soared 159742.65% — and 2024, when it plunged 99.9%.
- Tracing CASIF's Total Debt over 5 years: stood at $13.2 million in 2021, then retreated by 10.58% to $11.8 million in 2022, then soared by 159742.65% to $18.9 billion in 2023, then sank by 99.9% to $18.4 million in 2024, then climbed by 4.38% to $19.2 million in 2025.
- The last three Total Debt figures came in at $19.2 million (Q4 2025), $18.4 million (Q4 2024), and $18.5 billion (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 591.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.07 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 770.36 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 546.77 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.34 Bn |
| 10 | CASI Pharmaceuticals | 2.65 Mn | -3.76 Bn | - | 19.78 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 19.19 Mn |
| Dec 31, 2024 | 18.39 Mn |
| Jun 30, 2024 | 18.47 Bn |
| Mar 31, 2024 | 18.59 Mn |
| Dec 31, 2023 | 18.90 Bn |
| Dec 31, 2022 | 11.82 Mn |
| Dec 31, 2021 | 13.22 Mn |